You are here:

palonosetron (Aloxi)

Advice

following an abbreviated submission:

palonosetron soft capsules (Aloxi®) is accepted for use within NHS Scotland.

Indication under review: prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.

At recommended licensed doses the soft capsule formulation has been shown to be clinically non-inferior to the intravenous formulation and is cost neutral.

SMC has previously accepted palonosetron intravenous injection for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Drug Details

Drug Name: palonosetron (Aloxi)
SMC Drug ID: 838/13
Manufacturer: Sinclair IS Pharma
Indication: For the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
BNF Category:
Sub Category: 4.6 Drugs used in nausea and vertigo
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 11 February 2013

Back